Jazz Pharmaceuticals plc (J7Z) — Cash Flow Quality Index

Latest as of March 2026: 1.39x

Jazz Pharmaceuticals plc (J7Z) has a Cash Flow Quality Index of 1.39x as of March 2026. Operating cash flow of €408.20 Million exceeds net income of €293.10 Million, indicating high earnings quality where cash backs reported profits. Explore J7Z cash flow conversion to assess how effectively this company generates cash.

Cash Flow Quality Index

1.39x
Operating CF / Net Income

Operating Cash Flow

€408.20 Million
EUR

Net Income

€293.10 Million
EUR

Data as of

Mar 2026
Most recent filing

Jazz Pharmaceuticals plc Cash Flow Quality Index (2013–2024)

Historical Cash Flow Quality Index for Jazz Pharmaceuticals plc across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Jazz Pharmaceuticals plc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Jazz Pharmaceuticals plc (2013–2024)

Year-by-year earnings quality comparison for Jazz Pharmaceuticals plc. For live market cap and the full company financial profile, see Jazz Pharmaceuticals plc stock valuation.

Year Quality Index Operating CF (EUR) Net Income YoY Change
2024 2.49x €1.40 Billion €560.12 Million ▼ -5.3%
2023 2.63x €1.09 Billion €414.83 Million ▼ -30.2%
2020 3.77x €899.65 Million €238.62 Million ▲ +154.2%
2019 1.48x €776.40 Million €523.37 Million ▼ -17.0%
2018 1.79x €798.90 Million €447.10 Million ▲ +25.8%
2017 1.42x €693.09 Million €487.85 Million ▼ -4.8%
2016 1.49x €592.39 Million €396.83 Million ▼ -7.5%
2015 1.61x €531.94 Million €329.54 Million ▼ -76.9%
2014 6.98x €407.61 Million €58.39 Million ▲ +423.6%
2013 1.33x €288.43 Million €216.31 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.